Moreover, as predicted by the Ingenuity Pathway Analysis (IPA), we validated the involvement of SOX9 (15)—a newly identified marker for aggressive CRC based on a recent large-scale integrative analysis—in Gal-1/β-catenin interactions. Here, SOX9 is linked to colorectal carcinoma.